Dear BioPharmaPM members,

We are excited to announce our first keynote speaker for the 2025 BioPharmaPM Conference.

Ann Lee-Karlon, PhD, is the CEO of EpiBiologics, former COO of Altos Labs, and former Senior Vice President at Genentech.  EpiBiologics is advancing bispecific antibody protein degradation therapeutics with a wide range of applications, including oncology and immunology.
During her 18 years at Genentech, Ann led portfolio strategy and operations and had project leadership oversight for over 80 drug development teams from research and development through FDA approval and global launch.
Ann holds a BS in bioengineering from UC Berkeley, MBA from Stanford University, and PhD in bioengineering from UC San Diego, where she was a National Science Foundation Fellow. She completed her NSF postdoctoral fellowship at the University College London. Ann was the president and board chair of the Genentech Patient Foundation and president and board chair of the Association for Women in Science, based in Washington, D.C. She is a board member of Eko Health and serves on the Dean’s advisory boards for UC Berkeley and UCSD schools of engineering. Ann was elected Fellow of the American Institute for Medical and Biological Engineering and is a Fellow of the Aspen Institute.

Come join us to hear Dr. Ann Lee-Karlan and learn how to Lead through change.

Registration is now open for our 2025 conference. Click Here to register.

Kind regards,
Monica Miller & Silvia Cermelli
(2025 BPPM Conference Chairs)
With the support of BioPharmaPM Board of Directors

Dear BioPharmaPM members,

We are excited to announce our Second keynote speaker for the 2025 BioPharmaPM Conference.

Susan is an accomplished entrepreneur and investor with extensive experience in product design and development. She has successfully founded and led start-ups in the advertising, finance, retail, and media industries, driving digital transformation and fostering innovation. Susan holds a Master of Science in Management from Stanford GSB, where she remains actively engaged. She is also the founder of the Akbarpour Aalaei Fellowship, which grants scholarships to Farsi-speaking students at Stanford GSB.

Susan’s expertise in the rapidly evolving AI space has led her to serve on the boards of AI companies such as OII.AI, Facenote, Cluster (AKA Alogopix), and Entropy. Her contributions in these roles have been valuable in advancing the field. Additionally, Susan is deeply committed to advocating for public media and women’s empowerment and sits on the boards of non-profit organizations like KQED, How Women Lead, and Moms Against Poverty.

Currently, Susan holds the position of managing partner at Candou Ventures, an early

stage VC fund that focuses on investing in and supporting start-ups within the blockchain, AI, SAAS, IoT, and cloud infrastructure industries. She is also a limited partner in funds like How Women Invest, Practical Venture Capital, and Venture University Venture Partners. Furthermore, Susan has launched Democracy 3.0, a non-profit technology platform dedicated to combating the spread of misinformation and disinformation that led to the polarization of societies. Susan has received multiple media, community and business awards and She is also a contributor writer to Forbes, IPR Journal, Disruptor daily and is frequently featured in mainstream media.

Please join us to hear Susan guide us to explore how embracing these breakthroughs can accelerate decision-making, enhance efficiency, and elevate expertise rather than replace it. AI doesn’t take jobs- it takes the mundane, turning novices into experts and experts into visionaries. But embracing change isn’t just about learning new tools; it requires stepping outside our comfort zones and rethinking how we work.

We’ll also discuss how men and women may approach these shifts differently and how leveraging diverse perspectives can drive innovation.

Registration is now open for our 2025 conference. Click Here to register.

Kind regards,

Monica Miller & Silvia Cermelli
(2025 BPPM Conference Chairs)
With the support of BioPharmaPM Board of Directors